The authors present a concise and clear description of the issue of osteonecrosis of the jaw seen in patients undergoing antiresorptive therapy (ARONJ) using medicaments that modify the metabolism of the bones (BMA). Furthermore, they present the structure and appearance of the registry of patients who have suffered osteonecrosis of the jaw, and the access to the registry itself.
They emphasize the security of the entered data and the sbsequent statistical evaluation. Addictional emphasis is relayed upon prevention and cooperation between practical dentists, dental surgeons, and clinical departments, and last but not least among doctors who prescribe and manage these medications and treatment.